Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., nonbronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV), while nonbronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).
Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.
Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• Store below 30 C°
• Protect from light and freezing
• Injection 250mg/10ml: Box of 5 ampoules
AMINODIC®
Injection 250mg/10ml
Phosphodiesterase inhibitors
Bronchodilators
Category C
Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., nonbronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV), while nonbronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).
Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.
Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• Store below 30 C°
• Protect from light and freezing
• Injection 250mg/10ml: Box of 5 ampoules
AMINODIC®
[view] =>AMINODIC®
) ) [field_contraindications] => Array ( [0] => Array ( [value] => Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine. [format] => 1 [safe] =>Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
[view] =>Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
) ) [field_dosage_form] => Array ( [0] => Array ( [value] => Injection 250mg/10ml [format] => 1 [safe] =>Injection 250mg/10ml
[view] =>Injection 250mg/10ml
) ) [field_drug_interactions] => Array ( [0] => Array ( [value] => The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects: • alcohol; • cimetidine (Tagamet); • fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ; • clarithromycin and erythromycin ; • disulfiram (Antabuse); • estrogens (Premarin); • fluvoxamine (Luvox); • methotrexate ; • mexiletine and propafenone ; • propranolol (Inderal); • tacrine ; • ticlopidine ; and • verapamil . The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control: • aminoglutethimide (Cytadren), • carbamazepine (Tegretol), • isoproterenol , • moricizine , • phenobarbital , • phenytoin (Dilantin), • rifampin , and • sucralfate . [format] => 1 [safe] =>The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
[view] =>Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
) ) [field_packing] => Array ( [0] => Array ( [value] => • Injection 250mg/10ml: Box of 5 ampoules [format] => 1 [safe] =>• Injection 250mg/10ml: Box of 5 ampoules
[view] =>• Injection 250mg/10ml: Box of 5 ampoules
) ) [field_pdf] => Array ( [0] => Array ( [fid] => 167 [uid] => 1 [filename] => aminophyline.pdf [filepath] => sites/default/files/pdf/aminophyline.pdf [filemime] => application/pdf [filesize] => 142283 [status] => 1 [timestamp] => 1329485824 [list] => 1 [data] => [i18nsync] => 1 [nid] => 232 [view] => ) ) [field_pharmacokinetics] => Array ( [0] => Array ( [value] => Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance. theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline. [format] => 1 [safe] =>Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
[view] =>Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
) ) [field_pharmacological_category] => Array ( [0] => Array ( [value] => Phosphodiesterase inhibitors [format] => 1 [safe] =>Phosphodiesterase inhibitors
[view] =>Phosphodiesterase inhibitors
) ) [field_precautions] => Array ( [0] => Array ( [value] => Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose. [format] => 1 [safe] =>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
[view] =>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
) ) [field_pregnancy_category] => Array ( [0] => Array ( [value] => Category C [format] => 1 [safe] =>Category C
[view] =>Category C
) ) [field_references] => Array ( [0] => Array ( [value] => [format] => [safe] => [view] => ) ) [field_side_effects] => Array ( [0] => Array ( [value] => • an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives); • seizures; • increased or irregular heartbeats; or • severe nausea or vomiting. less serious side effects • slight nausea, decreased appetite, or weight loss; • restlessness, tremor, or insomnia; or • headache, lightheadedness, or dizziness. [format] => 1 [safe] =>• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
Bronchodilators
[view] =>Bronchodilators
) ) [field_related_products] => Array ( [0] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [1] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) [2] => Array ( [nid] => [i18nsync] => 1 [safe] => Array ( ) [view] => ) ) [taxonomy] => Array ( [6] => stdClass Object ( [tid] => 6 [vid] => 1 [name] => Antihistamines, Bronchodilators [description] => [weight] => 4 [language] => [trid] => 0 [v_weight_unused] => 0 ) ) [build_mode] => 0 [readmore] => 1 [content] => Array ( [field_one_image] => Array ( [#type_name] => product [#context] => full [#field_name] => field_one_image [#post_render] => Array ( [0] => content_field_wrapper_post_render ) [#weight] => -3 [field] => Array ( [#description] => [items] => Array ( [0] => Array ( [#formatter] => image_plain [#node] => stdClass Object *RECURSION* [#type_name] => product [#field_name] => field_one_image [#weight] => 0 [#theme] => imagefield_formatter_image_plain [#item] => Array ( [fid] => 166 [uid] => 1 [filename] => aminophyline_s.jpg [filepath] => sites/default/files/images/aminophyline_s.jpg [filemime] => image/jpeg [filesize] => 58901 [status] => 1 [timestamp] => 1329485617 [list] => 1 [data] => Array ( [alt] => [title] => ) [i18nsync] => 1 [nid] => 232 [#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>AMINODIC®
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>AMINODIC®
) [#title] => [#description] => [#children] =>AMINODIC®
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_brand_name [#title] => Brand Name [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>AMINODIC®
[#printed] => 1 ) [#title] => [#description] => [#children] =>AMINODIC®
Injection 250mg/10ml
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Injection 250mg/10ml
) [#title] => [#description] => [#children] =>Injection 250mg/10ml
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_dosage_form [#title] => Dosage Form [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Injection 250mg/10ml
[#printed] => 1 ) [#title] => [#description] => [#children] =>Injection 250mg/10ml
Phosphodiesterase inhibitors
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Phosphodiesterase inhibitors
) [#title] => [#description] => [#children] =>Phosphodiesterase inhibitors
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacological_category [#title] => Pharmacological Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Phosphodiesterase inhibitors
[#printed] => 1 ) [#title] => [#description] => [#children] =>Phosphodiesterase inhibitors
Bronchodilators
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Bronchodilators
) [#title] => [#description] => [#children] =>Bronchodilators
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_therapeutic_category [#title] => Therapeutic Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Bronchodilators
[#printed] => 1 ) [#title] => [#description] => [#children] =>Bronchodilators
Category C
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Category C
) [#title] => [#description] => [#children] =>Category C
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pregnancy_category [#title] => Pregnancy Category [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Category C
[#printed] => 1 ) [#title] => [#description] => [#children] =>Category C
Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., nonbronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV), while nonbronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).
Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.
Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
) [#title] => [#description] => [#children] =>Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_pharmacokinetics [#title] => Pharmacokinetics [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
[#printed] => 1 ) [#title] => [#description] => [#children] =>Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
) [#title] => [#description] => [#children] =>Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_indications [#title] => Indications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
[#printed] => 1 ) [#title] => [#description] => [#children] =>Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
) [#title] => [#description] => [#children] =>Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_contraindications [#title] => Contraindications [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
[#printed] => 1 ) [#title] => [#description] => [#children] =>Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
) [#title] => [#description] => [#children] =>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_precautions [#title] => Precautions [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
[#printed] => 1 ) [#title] => [#description] => [#children] =>Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
• Store below 30 C°
• Protect from light and freezing
• Injection 250mg/10ml: Box of 5 ampoules
[#delta] => 0 ) [#title] => [#description] => [#theme_used] => 1 [#printed] => 1 [#type] => [#value] => [#prefix] => [#suffix] => [#children] =>• Injection 250mg/10ml: Box of 5 ampoules
) [#title] => [#description] => [#children] =>• Injection 250mg/10ml: Box of 5 ampoules
[#printed] => 1 ) [#single] => 1 [#attributes] => Array ( ) [#required] => [#parents] => Array ( ) [#tree] => [#context] => full [#page] => 1 [#field_name] => field_packing [#title] => Packing [#access] => 1 [#label_display] => above [#teaser] => [#node] => stdClass Object *RECURSION* [#type] => content_field [#children] =>• Injection 250mg/10ml: Box of 5 ampoules
[#printed] => 1 ) [#title] => [#description] => [#children] =>• Injection 250mg/10ml: Box of 5 ampoules
AMINODIC®
Injection 250mg/10ml
Phosphodiesterase inhibitors
Bronchodilators
Category C
Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., nonbronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV), while nonbronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).
Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.
Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology and co-administration of other drugs can significantly alter the pharmacokinetic characteristics of theophylline. Within subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance.
theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.
Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Aminophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product including ethylenediamine.
Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose.
The following drugs may increase the levels of aminophylline in your blood, leading to dangerous side effects:
• alcohol;
• cimetidine (Tagamet);
• fluoroquinolone antibiotics such as enoxacin, lomefloxacin , ciprofloxacin , norfloxacin, and ofloxacin ;
• clarithromycin and erythromycin ;
• disulfiram (Antabuse);
• estrogens (Premarin);
• fluvoxamine (Luvox);
• methotrexate ;
• mexiletine and propafenone ;
• propranolol (Inderal);
• tacrine ;
• ticlopidine ; and
• verapamil .
The following drugs may decrease aminophylline levels in your blood, leading to poor asthma control:
• aminoglutethimide (Cytadren),
• carbamazepine (Tegretol),
• isoproterenol ,
• moricizine ,
• phenobarbital ,
• phenytoin (Dilantin),
• rifampin , and
• sucralfate .
• an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
• seizures;
• increased or irregular heartbeats; or
• severe nausea or vomiting.
less serious side effects
• slight nausea, decreased appetite, or weight loss;
• restlessness, tremor, or insomnia; or
• headache, lightheadedness, or dizziness.
• Store below 30 C°
• Protect from light and freezing
• Injection 250mg/10ml: Box of 5 ampoules
(C) Copyright Caspian Tamin Pharmaceutical Co.
All Rights Reserved.